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ABSTRACT
Chronic pancreatitis is a progressive inflammation in pancreas results in fibrosis and irreversible damage lead 
to loss of exocrine and endocrine function. Mortality and complication rate is high. Appropriate management of 
chronic pancreatitis begin from accurate diagnosis to adequate treatment. Diagnosis is still a challenge for clinician, 
mostly in early-stage disease. Several diagnostic modalities such computed tomography scan, magnetic resonance 
cholangiopancreaticography, endoscopic ultrasound, endoscopic retrograde cholangiopancreaticography, and 
direct-indirect pancreatic function test help diagnosis establishment. Endoscopic approach has an important 
role, both during diagnosis and treatment. 
Keywords: chronic pancreatitis, endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, 
direct pancreatic function testing, indirect pancreatic function testing
ABSTRAK
Pankreatitis kronis merupakan peradangan kronis pada pankreas, bersifat progresif, disertai adanya jaringan 
parut, yang merusak pankreas secara ireversibel, dan mengakibatkan hilangnya fungsi eksokrin dan endokrin 
dari pankreas. Kasus ini memberikan konsekuensi mortalitas dan komplikasi yang cukup besar. Pengelolaan 
pankreatitis kronik yang tepat bermula dengan penegakkan diagnosis secara akurat. Ini menjadi tantangan 
tersendiri terutama pada pasien yang masih dalam stadium awal, dimana tidak selalu memberikan bukti definitif 
pankreatitis kronik. Berbagai modalitas diagnostik seperti computed tomography scan (CT Scan), Magnetic 
resonance cholangipancreoticography (MRCP), hingga penunjang perendoskopik baik itu endoscopic ultasound 
(EUS) dan endoscopic retrograde cholangiopancreatography (ERCP), dan uji fungsi pankreas langsung dan tak 
langsung, dapat membantu penegakkan diagnosis pankreatitis kronik. Penunjang perendoskopik (EUS maupun 
ERCP) tidak hanya memberikan pencitraan tapi juga sebagai modalitas terapi. 
Kata kunci: pankreatitis kronis, endoscopic ultrasound, endoscopic retrograde cholangiopancreatography, 
direct pancreatic function testing, indirect pancreatic function testing
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INTRODUCTION
Chronic pancreatitis is defined as progressive 
chronic inflammation of pancreas tissue that lead to 
fibrosis. It irreversibly damaged pancreatic tissue, so 
both exocrine and endocrine function could loss over 
the time.1 
A population-based study across countries reported 
global incidence of 4.4 – 11.9 per 100,000 population 
annually. Male was having higher incidence 1.5-3 times 
than female.2-9 It prevalence was relatively low, account 
to 36.9-41.8 cases in 100,000 population.4,5 Study 
by Siecean et al reported mortality among chronic 
pancreatitis patients is 17% during first 59 month 
after diagnosis. Cause of mortality were malignancy 
(3.6%), surgical complication (3.6%), and upper 
gastrointestinal tract bleeding (2.4%).10 
Management of chronic pancreatitis is still 
challenging. Yet, none treatment was said to be 
effective to slow its progression nor improve clinical 
condition. Several new evidence have been revealed in 
chronic pancreatitis management. A good management 
was started by accurate diagnosis, followed by 
adequate treatment since patients have various signs 
and symptoms.11
DEFINITION 
Chronic pancreatitis described as fibroinflammatory 
disease that damage pancreatic tissue and lead to 
exocrine and endocrine function loss.12
ETIOLOGY AND CLASSIFICATION
Chronic pancreatitis is a disease entity, classified 
into three main form: (1) chronic calcific pancreatitis; 
(2) chronic obstructive pancreatitis; (3) chronic 
autoimmune pancreatitis (steroid-responsive 
pancreatitis). Clinical presentations were vary based on 
its etiology, but the main symptom is abdominal pain.12
Chronic Calcific Pancreatitis
Chronic calcific pancreatitis development begins 
with acute pancreatitis. As disease progress, intraductal 
stone (in main or branch pancreatic duct), duct 
distortion, stricture, and pancreatic tissue atrophy 
appeared. Extensive parenchym destruction would lead 
to steatorrhea and diabetes. Others chronic pancreatitis 
type were rarely forming a clacification.12
Chronic Obstructive Pancreatitis 
Chronic obstructive pancreatitis was defined as 
chronic pancreatitis results from primary disease 
in pancreatic duct or obstruction (both complete or 
partial) of pancreatic duct. Obstruction mostly caused 
by stricture, as a complication from endoscopic 
procedure, surgery, acute necrotizing pancreatitis, 
abdominal blunt trauma, narrowing of pancreatico-
enteric anastomosis, and obstructing tumor (ductal 
adenocarcinoma or intraductal papillar mucinous 
tumor). Later, this could lead to chronic calcific 
pancreatitis. In obstructive pancreatitis, only proximal 
area that affected while distal pancreatis function is 
reserve. Partial obstruction of pancreatic duct increase 
the risk of recurrent acute pancreatitis. Most of chronic 
obstructive pancreatitis is asymptomatic.12 
Chronic Autoimmune Pancreatitis
Chronic autoimmune pancreatitis is a unique type 
of pancreatitis which the inflammation is responsive to 
steroid therapy. Chronic autoimmune pancreatitis was 
classified into type 1 and 2, which contrastly different. 
The word ‘autoimmune’ was more relevant for type 1 
disease, so that several expert labelled type 2 chronic 
autoimmune pancreatitis as ductal idiopathic chronic 
pancreatitis.13 Type 1 autoimmune pancreatitis is mainly 
manifest as multiorgan fibroinflammatory syndrome, 
highly correlate to immunoglobulin G4 (IgG4), 
characterized by increase serum IgG4 concentration, 
multiorgan involvement, typical histologic findings, 
and responsive to corticosteroid and B cell depletion 
therapy. IgG4 related disease affect several organs, 
including pancreas, biliary duct, salivary duct, kidney, 
and lymph nodes.14 Histologically, this disease marked 
as lymphoplasmacytic infiltration around duct, 
storiform fibrosis, heavy inflammation on vein that 
could spread to adjacent rteries, and abundance of IgG4 
positive plasma cell (>10/high power field).12 Common 
form of type 1 autoimmune chronic pancreatitis is 
an obstructive jaundice. Pain is not dominant and 
relieved after steroid administration. Unfortunately, 
Table 1. Chronic pancreatitis classification 12
Chronic 
calcific 
pancreatitis
Chronic obstructive 
pancreatitis
Chronic 
autoimmune 
pancreatitis
Alcohol Stricture: Blunt trauma Autoimunne
Smoking Post endoscopic stenting Type 1
Genetic Acute pancreatitis Type 2
Idiopathic:
Juvenille onset,
Tropical
Senile onset
Anastomosis stricture
Tumor:
Adenocarsinoma, 
intraductal papillary 
mucinous neoplasm 
(IPMN), serous 
cystadenoma, Islet cell 
tumor
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relaps rate was high in this condition.15 On the other 
hand, ductal idiopathic chronic pancreatitis (type 2 
autoimmune pancreatitis) was substantially differ to 
type 1 autoimmune pancreatitis. Histologically, duct 
obliteration in type 2 autoimmune pancreatitis was 
resulted from neutrophil infiltration in duct epithelial 
layer. 
dependent, estimate about 3.3 (95% CI: 1.4-7.9) in 
smoker more than 1 pack everyday, compared to 2.4 
(95% CI: 0.9-9.6) in non-heavy smokers. People who 
have been smoking in the past also had higher risk 
to develop chronic pancreatitis (HR = 1.59; 95% CI: 
1.1.9 -2.12).24 In vitro study showed that nicotine and 
its metabolite induce oxidative stress in pancreatic 
acinar cell.25,26 
Genetic
In the last two decades, several studies have 
identified specific gen that increase the predisposition 
to develop chronic pancreatitis, by premature 
trypsinogen activation ot by failure to inactivate 
trypsin during inflammation process. Previous 
research identified mutation in cationic trypsin gene 
(PRSS1) that prematurely activate trypsinogen, lead to 
hereditary pancreatitis.27 This was autosomal dominant 
trait with high penetration rate, as affected individual 
showed clinical symptoms. Inhibitor of serum protease, 
SPINK1, expressed by acinar cell during inflammatory 
response also encode trypsin inhibitor. Although 
SPINK1 mutation was not an independent risk factor, 
it could modify disease and involve in transformation 
from acute to chronic pancreatitis.28 This mutation 
was highly related to trophic calficic pancreatitis.29 
Mutation in CFTR (cause of cystic fibrosis) was also 
found in chronic idiopathic pancreatitis.30,31 CTRC, 
CASR, and CLDN1 gene in X chromocome were 
also highly correlate to chronic pancreatitis.12,32-34 
Hereditary pancreatitis secondary to PRSS1 mutation 
increase the risk of adenocarcinoma development in 
pancreatis tissue.35
Ductal Obstruction
Ductal obstruction caused by inflamed stricture, 
benign tumor, or malignancy could lead to chronic 
obstructive pancreatitis. Patient with CFTR mutation 
have higher risk of divisum pancreas.36,37 Patophysiology 
of those phenomena is still unknown.
Idiopathic
In most cases, the etiology of chronic pancreatitis 
is unknown. Before classified as idiopathic, all 
examination panel should be done. Tropical pancreatitis, 
known as fibrocalculous diabetic pancreatitis, is an 
early form of idiopathic pancreatitis in tropical region. 
South India has the highest prevalence of this chronic 
pancreatitis, marked as early onset of pain, calcification 
in main pancreatic duct, and rapid-onset ketosis that 
Table 2. Characteristic of chronic autoimmune pancreatitis12
Type 1 Type 2
Median age 7th decade 3rd decade
Gender Male predominant Equal 
Other organ involvment Frequent (60%) None
Inflammatory bowel disease < 10% 30%
Increase serum IgG4 > 80% < 10%
Histologic findings:
Granulocyte epithelial lesion
IgG4 (+) staining
Not present
Prominent
Present
Rarely
Response to steroid therapy Universal Universal
Relapse after steroid therapy 30-60% < 10%
Risk Factors
Alcohol
Traditionally, alcohol was known as main risk 
factor of chronic pancreatitis. Epidemiologic study in 
US reported that almost 50% of chronic pancreatitis 
was caused by alcoholism.17 Alcoholism was risk 
factor for chronic pancreatitis, both alone (34%) or as 
a combination to ductal obstruction (9%) and higher 
proportion in male (59% vs. 28%).18 Recently, a locus 
gen CLDN2 was identified and related to alcoholism as 
risk factor of pancreatitis.19 Homozygosity frequency 
were higher in male (0.26 vs. 0.07) thus strengthen the 
evidence and role of gender to alcoholism and chronic 
pancreatitis. 
The risk of chronic pancreatitis was correlate 
to alcohol intake dose. Recent case control and 
meta analysis showed that 2-3 times higher risk to 
develop pancreatitis if consuming 4-5 portion of 
alcohol everyday.20,21 No exact threshold of alcohol 
consumption that increase the risk of chronic 
pancreatitis. Alcohol increase acinar cell damage 
by interfering its defence mechanism against tissue 
oxidative stress.23
Cigarette Smoking
Cigarrete smoking is an independent risk factor of 
chronic pancreatitis. In a meta analysis, estimate risk 
of chronic pancreatitis among smoker was 2.5 (95% 
CI: 1.3-4.6) compared to non-smoker (after alcohol 
consumption adjustment).20. 24 Relationship between 
cigarette smoking and chronic pancreatitis was dose-
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resistant to diabetes treatment. Even genetic (SPINK1), 
nutrition, and inflammatory factors have implication 
in this condition, the basic pathogenesis is still 
questionable.38 
PATHOGENESIS
Underlying mechanism of chronic pancreatitis 
begin with pancreatic stellate cell (PCS) activity. 
Triggering factor (alcohol and toxic metabolic strees) 
initiate the spontaneous acute pancreatitis episode 
(SAPE). This inflammation could be suppressed if 
triggering factor present only in a short time. On the 
other hand, repeat exposure to triggering factor would 
lead to persisten recurrent acute pancreatitis (RAP), 
and lately activate PCS. TNF-related apoptosis-
inducin ligand = proinflammatory cytokine (TRAIL)
and other chemokine from inflammatory process and 
PCS activation would induce parenchymal damage, 
later develop to fibrosis, that finally manifest as ductal 
obstruction, dilatation, or increase in pressure. This 
long-term remodeling of duct could activate signaling 
pathway (e.g Notch and Hedgehog) that lead to cellular 
transformation, resulting in acinoductal metaplasia 
(ADM), pancreatic intraepithelial neoplasia (PanIN), 
and pancreatic ductal adenocarcinoma.39 Under 
influence of IFN-gamma released by lymphocyte 
CD4+ and CD8+, this acinar cell would express 
CD95, TRAIL R1, and TRAIL R2 which related to 
intracellular death. Therefore, pancreatic acinar cell 
was considered as susceptible to apoptosis by T cell 
that express CD95L and TRAIL, locally produced by 
PSC. Acinar cell death in chronic pancreatitis also 
related to perforin granzim B. Otherwise, pancreatic 
island maintains CD95L (+) status and negative status 
(death receptor) and neoexpression of TRAIL R4. 
NF-kB is expressed in islet cell that activate inhibitor 
apoptosis proteins (IAPs) to protect islet cell. At the 
end of obstruction process, dilatation and increase 
of intraductal pressure in chronic pancreatitis would 
activate Notch and Hedgehog signaling pathway 
that further increase the risk of ADM and PanIN 
development.39
CLINICAL MANIFESTATION
Chronic pancreatitis main characteristic is 
progressive damage of pancreatic tissue. After 
subclinical phase that have various duration, recurrent 
acute abdominal pain is often and followed by 
insufficiency of both endocrine and exocrine secretion 
function.40 Predominant complaint are abdominal pain, 
Figure 1. Pathogenesis of chronic pancreatitis39
Figure 2. Concept of novel integration in cellular, genetic, and 
molecular mechanism in chronic pancreatitis39
maldigestion, or unintended weight loss. Abdominal 
pain varies according to location, severity, or frequency, 
could be constant or intermittent. Food intake would 
propagate abdominal pain, so that most patient refuse 
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to eat, leading to weight loss. Maldigestion shown as 
chronic diarrhea, steatorrhea, weight loss, and fatigue. 
Patient with chronic abdominal pain was not always 
progress to maldigestion, and about 20% patient 
with maldigestion do not complain abdominal pain. 
Steatorrhea do not correlate to deficiency of lipid-
soluble vitamin. Patient with chronic pancreatitis have 
examination. Common findings during abdominal 
USG is calcification of pancreas, shown as multiple 
ecogenic focus (found in 40% patients). Otherwise, 
no correlation between pancreatic function and the 
size of calcification. Other findings during USG are 
change in size and echogeneity of pancreatic gland, 
dilatation, and irregularity of pancreatic duct. USG also 
Table 3. Clinical manifestation, complication, and comorbidities 
among  chronic pancreatitis patient42
Findings n (%)
Weight loss 45 (43.3)
Steatorrhea 14 (13.5)
Pancreatitic Diabetes melitus 31 (29.8)
Calcification 11 (10.6)
Pancreatitic pseudocyst 28 (26.9)
Dyspepsia 45 (43.3)
Jaundice 10 (9.6)
Splenomegaly 10 (9.6)
Pancreatitic Ascites 10 (9.6)
Esophagogastric varices 1 (1.0)
Portal vein thrombosis 1 (1.0)
Variceal colon 1 (1.0)
Duodenal stenosis 1 (1.0)
Erotion or ulcer in gastroduodenal mucosa 8 (7.7)
Anemia 30 (28.8)
Hypoproteinemia 22 (21.2)
Alcoholic cirrhosis 1 (1.0)
Tuberculosis 1 (1.0)
Pancreatititc carcinoma 3 (2.9)
Other malignancy
 Gastric carcinoma 2 (1.9)
 Cholangioma 1 (1.0)
 Carcinoma of ampulla 2 (1.9)
Sjogren syndrome 1 (1.0)
Hypothyroidsm 1 (1.0)
Diabetes Mellitus type 1 2 (1.9)
high social impairment.41 
CONFIRMATORY WORKUP
Transabdominal ultrasonography (USG) and 
computed tomography scan (CT Scan) play an 
important role in diagnosis confirmation. Diagnosis 
using USG and CT Scan rely on morphological changes 
which is less seen in early-stage of chronic pancreatitis. 
Diagnosis establishment even getting harder since 
histological confirmation is unusual in clinical practice. 
The main findings are glandular atrophy, chronic 
inflammation, and fibrosis in pancreatis tissue. Others 
are main and branches pancreatic duct dilatation and 
intraductal calcification.1 
Abdominal USG
Abdominal USG has been used in recent year to 
evaluate pancreas, yet no new study to investigate 
the role of high-end USG in chronic pancreatitis 
diagnosis. Even with good visualization, USG was 
less sensitive and specific in chronic pancreatitis 
could examine pseudocyst, biliary duct dilatation, and 
splenic vein thrombosis, as a complication of chronic 
pancreatitis.1
CT Scan
CT scan is the best imaging study in chronic 
pancreatitis. Classic finding is pancreatic duct 
dilatation, calcification, and parenchymal atrophy. 
Of chronic pancreatitis cases, about 68% have 
pancreatic duct dilatation and 50% having intraductal 
calcification, both focal or diffuse. Other findings 
are parenchymal atrophy (54%), enlarging pancreas 
(30%), or even normal pancreas (7%). CT scan could 
also detect any complication such as pseudocyst, 
portosplenic vein thrombosis, pseudoaneurysm, 
and fistula pancreaticopleura. At some point, CT 
Figure 3. Pancreatic calcification in USG1
scan evaluation can differ chronic pancreatitis with 
pancreatic cancer by finding obstruction related to 
tumor, pancreatic tissue atrophy, vascular invasion, or 
any sign of metastasis.1
Figure 4. “Duct-penetrating sign” in chronic pancreatitis1
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Magnetic Resonance Imaging (MRI)
MRI is another imaging modality that possible to 
detect early-stage disease, so that early intervention to 
prevent progressivity can be planned. MRI has high 
sensitivity and specificity to evaluate any changes in 
pancreatic tissue. Parenchym evaluation in MRI showed 
low intensity at duct in chronic pancreatitis cases. By 
injecting intravenous secretin, MRI can also diagnose 
chronic pancreatitis by evaluating exocrine secretion 
response. The focus was in pancreatic duct compliance 
(PDC) defined as normal duct distention + 1 mm after 
secretin stimulation and reversal to baseline diameter 
10 minutes after injection.1 Sometimes, parenchymal 
abnormalities precede ductal abnormalities. Cambridge 
classification is used to evaluate any abnormalities in 
duct, stricture, cyst formation, or intraductal stone.
Endoscopic Ultasound (EUS)
Endoscopic ultrasound (EUS) is a common 
diagnostic tool for chronic pancreatitis because 
of its ability in evaluating minimal changes in 
pancreatic structure before able to detect by other 
modalities. Diagnosis using EUS based on ducatal 
and parenchymal criteria established by International 
Working Group with Minimum Standard Terminology 
(MST). Chronic pancreatitis morphology in EUS is: (1) 
hyperechoic and strand foci; (2) Lobular pancreas;  (3) 
irregular and dilated pancreatic duct; (4) marginal duct 
hyperechoic; (5) calcification or shadowing stones. 
Although EUS was recently developed well in other 
disease evaluation, the use of this tools in chronic 
pancreatitis diagnosis is stagnant in the last decade. 1
Endoscopic retrograde cholangiopancreatography 
(ERCP) 
Because chronic pancreatitis mainly diagnosed by 
finding changes in main and branch pancreatic duct, 
In general, ERCP gave an important additional 
diagnostic information although it rarely uses in chronic 
pancreatitis. Correlation between pancreatogram 
abnormalities and histological findings is found higher 
in late-stage disease rather dan early-stage. Weakness 
of this modalities is its invasiveness and having a 
risk of postprocedural complication, such as acute 
pancreatitis. ERCP also only visualize duct anatomy, 
but not for parrenchym.1
Indirect Pancreatic Function Testing
Indirect pancreatic testing such as serum trypsinogen, 
fecal elastase, and fecal fat do not need direct hormonal 
stimulation. This testing only sensitive to patinet with 
steatorrhea and use if direct testing unavailable or 
intolareated by patient. Indirect pancreatitis function 
testing should minimally examine two parameters. For 
example, a serum trypsin with < 20 pg/dL and fecal 
elastase < 50 ug/dL is suggestive of chronic pancreatitis. 
Unfortunately, fecal fat level is not specific for chronic 
pancreatitis and fecal chymotrypsin only available in US.1 
Direct Pancreatic Function Testing (PFT)
This testing could detect secretion problem in 
30% damaged pancreatic tissue, with high sensitivity 
mainly in late-stage chronic pancreatitis. Secretin 
stimulated direct PFT using traditional dreiling tube 
is accurate to estimate pancreatic duct function.43 
Weakness of this examination is uncomfortable for 
patient, need fluoroscopy, and the availability of the 
traditional dreiling tube. Patient with gastroparesis 
and pyloric stenosis also not compatible with this 
examination. Other direct PFT is CCK that measure 
acinar cell function. Weakness of this test is tube 
availability, fluoroscopy, PEG/mannitol marker, and 
CCK continuous infusion during examination. No 
advantage of combining secretin and CCK testing.1
Endoscopic Pancreatic Function Test (ePFT)
This test is developed by Cleveland Clinic. After 
sedated, patient injected by secretin bolus (0,2 mcg/kg) 
and followed with duodenal fluid aspiration and analysis. 
This test is simpler and do not need fluoroscopy. 
ePFT and dreiling tube test is the gold standard of 
non-histologic examination in early-stage chronic 
pancreatitis. In daily clinical practice, suspected chronic 
pancreatitis patient benefits more with combination of 
EUS and ePFT test, mainly to detect any structural and 
functional abnormalities in pancreas.1
Table 4. Cambridge criteria1
Grade Main pancreatic duct Duct branches
Normal Normal Normal
Equivocal Normal <3 Abnormal
Ringan Normal ≥3 Abnormal
Sedang Abnormal >3 Abnormal
Berat* Abnormal > 3 Abnormal
*including: large cavity > 10 mm, intraductal filling defect, duct obstruction 
(stricture), duct dilatation and iregularity, pancreatic calficication/stone, 
adjacent organ invasion
a high-quality pancreatogram is needed to accurately 
visualize duct anatomy. Contrast injected along duct 
to caudal, including secondary branches to avoid 
contrast acinarization. The widely accepted criteria in 
pancreatogram is Cambridge criteria:1
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CORRELATION BETWEEN RADIOLOGIC, 
FUNCTION TEST, AND HISTOLOGIC FINDINGS
Mild exocrine insufficiency is commonly found 
in mild to severe pancreatitis, while structural 
fibrosis reflects pancreas exocrine function. But, 
no linier relation between radiologic, function test, 
and histological findings. Previous study showed 
suboptimal concordation of ERCP result and PFT, 
mostly in early-stage disease. Concordation level of 
secretin PFT and ERCP in chronic non-calcifying 
pancreatitis is less than 47%. Nowadays, EUS is 
preferred because of its safety and ability to evaluate, 
although still suboptimal.1
DIAGNOSTIC ALGORITHM
In establishing chronic pancreatitis diagnosis, 
definitive diagnostic findings should be present, 
supported with risk factors above. Longitudinal follow-
up of serial radiologic examination and functional test 
is recommended in undetermined. Diagnostic algoritm 
can be seen in Figure 5.
TREATMENT
Treatment of chronic pancreatitis depend on the 
etiology, calcification, severity, and staging. Lifestyle 
such as alcohol consumption also a consideration in 
treatment.42 This disease classified into compensated, 
transitional, and uncompensated phase. Because of 
possible exocrine disfunction, both pharmacological 
and nutritional treatment is important.42
In compensated phase, the main goal is to control 
relaps and pain. Main approach in this phase is 
nutritional dietary and pharmacotherapy with protease 
inhibitor. In uncompensated phase, along with digestion 
and absorption dysfunction, patient should avoid low 
fat diet. Steatorrhea should be controlled with adequate 
fat intake (50-70 g/day) followed by digestive enzyme 
administration. Available oral pancreatic enzyme is 
pancrelipase. Other consideration in this phase is low 
bicarbonate secretion that lower proximal duodenal pH. 
If duodenal pH lower than 4, bile and several digestive 
enzymes could be coagulating. Therefore, antacid, H2 
receptor agonist, or proton pump inhibitor can be added 
to increase pH.42 Pancreatic diabetes is a complication 
in uncompensated phase, so that glucose level should 
Figure 5. Diagnostic algorithm
Step 1: Review of data, risk factors, and CT Scan result 
Step 2: CT Scan with pancreatic protocol, MRI/secretin-MRCP 
Step 3: Endoscopy-EUS (Stanard criteria) 
Step 4: Pancreatic Function Test (Dreiling, ePFT) 
Step 5: ERCP (wth therapeutic intervention) 
 
Figure 5. Diagnostic algorithm 
TREATMENT 
Treatment of chronic pancreatitis depend on the etiology, calcification, severity, and 
staging. Lifestyle such as alcohol consumption also a consideration in treatment.42 This disease 
classified into compensated, transitional, and uncompensated phase. Because of possible 
exocrine disfunction, both pharmacological and nutritional treatment is important.42 
Start
• Sign and symptom of chronic pancreatitis: abdominal pain, weight loss, steatorrhea, malabsorption, alcoholism history, 
recurrent pancreatitis, fat intolerant
• Cinical findings, laboratory examination, fecal elastase test (comparison)
Step 1
•CT Scan
•Diagnostic criteria: calcification combined with ductal atrophy and ot dilatation
•If fulfill criteria above, no further radiologic examination needed
•If inconclusive, continue to Step 2 below
Step 2
•MRI/MRCP with secretin injection
•Diagnostic criteria: Cambride criteria class III, ductal dilatation, gland atrophy, fillict defect suestive of pancreatic stone
•If fulfill criteria above, no further radiologic examination needed
•If inconclusive, continue to Step 3 below
Step 3
• Endoscopic ultrasound (EUS) with quanification using criteria
• Diagnostic criteria: ≥ 5 criteria of chronic pancreatitis in EUS
• If fulfill criteria above, no further radiologic examination needed
• If inconclusive, continue to Step 4 below
Step 4
• Pancreatic Function Test (with secretin)-gastroduodenal (SST) atau or endoskopik (ePFT)
• Diagnostic criteria: bicarbonate peak < 80 meq/L
• If fulfill criteria above, no further radiologic examination needed
• If inconclusive, continue to Step 5 below
• Note: consider combination of EUS with ePFT
Step 5
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Diagnostic criteria: Cambridge III, main pancreatic duct dilatation, and >3 branch dilated
• If fulfill criteria above, no further radiologic examination needed
• if inconclusive, longitudinal follow-up and repeat testing for 6 months - 1 year
Chronic Pancreatitis 
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be monitored closely. Algorithm of chronic pancreatitis 
treatment is shown in Figure 6 and Figure 7.
Lifestyle Modification
If chronic pancreatitis etiology is alcoholism, 
abstinence is the main treatment. Besides, stop smoking 
also help to relieve chronic pancreatitis since it triggers 
the development of calcification in pancreas parenchym. 
A deep consultation is needed to ensure patient 
compliance in stop alcohol consumption and smoking.42 
Abdominal and back pain is the main contributor to 
low quality of life in chronic pancreatitis patient. Social 
impairment and nutritional problem related to inability 
in food digestion is the most serious problem faced by 
both patient and treating physician. Dietary management 
is the key success of chronic pancreatitis patient, 
especially with abdominal pain as dominant symptom.42
ROLE OF ENDOSCOPY IN CHRONIC PANCREATITIS 
TREATMENT
European Society of Gastroenterology (ESGE) 
recommend endoscopic approach as first line in chronic 
pancreatitis without severe complication that have 
severe pain complaint.43
Pancreatic duct decompression is the first line 
therapy in patient with intraductal obstruction and 
hypertension via sphincterotomy, litotripsy, extraction, 
or stent placement. ESGE recommend extracorporeal 
shockwave lithotripsy (ESWL) in chronic pancreatitis 
with pancreatic stone > 5 mm, continued with stone 
extraction (stone size should < 5 mm). Intraductal 
lithotripsy is suggested if ESWL approach failed.43 
For stricture, dilatation using balloon or catheter is the 
best approach, continued by plastic stent placement. If 
success, this decompression would lead to pain relieve. 
EUS-guided drainage in main pancreatic duct that 
punctured via gaster or duodenum to make a fistula for 
drainage is the second line.43 EUS-guided celiac plexus 
block is another approach to relieve pain. Chemical 
sympathectomy using absolute alcohol injection will 
result in anesthesia for 8-12 months. Pain exacerbation 
48 hours after procedure occur in 9% patients.43
Endoscopic approach is the first line in chronic 
pseudocyst formation without complication. Drainage 
method consist of transpapillary/transductal endoscopic 
drainage and EUS-guided drainage.43 Transpapillary/
transductal endoscopic drainage for 4-6 weeks period 
is recommended in small pseudocyst which connect to 
main pancreatic duct. Otherwise, EUS-guided drainage 
Figure 7. Surgical approach in chronic pancreatitis42
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is indicated in portal hypertension or absent of luminal 
bulging cases. Complication rate is 18%, mainly about 
bleeding, infection, perforation, and stent migration.43
PROGNOSIS
In general, chronic pancreatitis is a progressive 
inflammatory disease. Observation and evaluation of 
clinical symptoms such as pain, enzymatic changes 
overtime, pancreas morphology, and exocrine-
endocrine function is important in prognostication. 
Chronic pancreatitis patient has more risk to develop 
pancreatic cancer, supported by their lifestyle which 
is carcinogenic (alcohol, smoking).42 
CONCLUSION
Diagnosis of chronic pancreatitis is still challenging, 
especially patient in early-stage disease. Risk factor 
assessment is important in evaluating patient with 
abdominal pain as chief complaint. Diagnosis 
should only establish if definite diagnostic findings 
is found. Several workup for chronic pancreatitis 
patient are CT Scan, MRI, or MRCP. Management 
of chronic pancreatitis consist of counseling and 
multidisciplinary approach in pain management, 
enzyme replacement therapy, endoscopic intervention, 
or surgery. Appropriate management of chronic 
pancreatitis would reduce its mortality and recurrence 
in the future.
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